News | April 04, 2025
SPARC announces submission of IND Application for SBO-154 to USFDA
The IND application supports the next phase of development of SBO-154
The IND application supports the next phase of development of SBO-154
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Subscribe To Our Newsletter & Stay Updated
